Engelmann M D, Henriksen S D, Tingsgaard L K
Organkirurgisk afdeling Hiørring Sygehus.
Ugeskr Laeger. 1995 Jul 31;157(31):4357-8.
We report a fatal case of haemorrhagic pancreatic necrosis in a 15-year-old mentally retarded epileptic male who had been taking sodium valproate (VPA) in the recommended dosage for one and a half years. The patient was admitted to hospital because of acute abdominal pain, with nausea and vomiting. Serum amylase was 609 U/l (normal range 100-360 U/l). Two exploratory laparotomies were performed. The second revealed haemorrhagic pancreatitis with areas of necrosis. VPA therapy was discontinued after the second laparotomy, but the patient died 25 days after admission. Autopsy showed extensive haemorrhagic pancreatic necrosis. Non-specific vomiting and abdominal pain occur frequently during VPA therapy, but VPA-related pancreatitis should be considered when there is severe abdominal pain with nausea and vomiting. Awareness of this problem and early discontinuation of VPA therapy may prevent serious reactions.
我们报告一例15岁智力发育迟缓的癫痫男性患者发生出血性胰腺坏死的致死病例,该患者已按推荐剂量服用丙戊酸钠(VPA)一年半。患者因急性腹痛伴恶心、呕吐入院。血清淀粉酶为609 U/l(正常范围100 - 360 U/l)。进行了两次剖腹探查术。第二次探查显示为出血性胰腺炎伴坏死区域。第二次剖腹探查术后停用了VPA治疗,但患者在入院25天后死亡。尸检显示广泛的出血性胰腺坏死。在VPA治疗期间,非特异性呕吐和腹痛很常见,但当出现严重腹痛伴恶心、呕吐时,应考虑与VPA相关的胰腺炎。认识到这个问题并早期停用VPA治疗可能预防严重反应。